← Back to Clinical Trials
Recruiting NCT07000851

Imaging Studies in Corticobasal Syndrome

Trial Parameters

Condition Cortico Basal Degeneration
Sponsor Jennifer Whitwell
Study Type OBSERVATIONAL
Phase N/A
Enrollment 80
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2025-06-25
Completion 2030-03-30
Interventions
C-11 ER176 RadiotracerC-11 PiBAV1451 Tau

Brief Summary

The primary goal of this study is to investigate inflammation and white matter damage in corticobasal syndrome and determine whether these processes are related to each other. The investigator's will address our goal by using neuroimaging and blood plasma biomarkers, as well as molecular pathology.

Eligibility Criteria

Inclusion Criteria: * Age 18 years or older * Meet possible or probable CBS criteria Exclusion Criteria: * Subjects will be excluded if MRI is contraindicated (due to implanted device, severe claustrophobia, etc) * Subjects will be excluded if they have a concurrent illnesses or structural abnormality that could account for the CBS syndrome * Subjects will be excluded if they have a mutation in the progranulin gene * Subjects will excluded if they have received anti-Aβ therapy * Women who are pregnant will be excluded * Subjects will be excluded if they are actively taking daily anti-inflammatory medications (NSAIDs, corticosteriods, etc) * Subjects will be excluded if they have generalized inflammatory condition and treatment with immunosuppressive, corticoid/glucocorticoid, steroidal or non-steroidal anti-inflammatory medication within 2 weeks of scanning

Related Trials